EDAP TMS (NASDAQ:EDAP) Releases Quarterly Earnings Results

Key Points

• EDAP TMS reported a quarterly earnings per share of ($0.17), slightly outperforming the consensus estimate of ($0.18).
• The company has a market cap of $59.08 million and is currently rated as a "Hold" by analysts, with an average price target of $8.50.
• EDAP TMS operates in the development and marketing of minimally invasive medical devices, specifically for urological diseases using High Intensity Focused Ultrasound (HIFU) technology.

EDAP TMS (NASDAQ:EDAP - Get Free Report) announced its quarterly earnings data on Thursday. The medical equipment provider reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.01, Zacks reports. EDAP TMS had a negative net margin of 34.45% and a negative return on equity of 51.42%.

EDAP TMS Price Performance

Shares of EDAP stock opened at $1.58 on Thursday. The company has a quick ratio of 1.21, a current ratio of 1.74 and a debt-to-equity ratio of 0.10. The firm has a market cap of $59.08 million, a price-to-earnings ratio of -2.55 and a beta of -0.09. The stock has a 50-day moving average price of $1.49 and a 200 day moving average price of $1.85. EDAP TMS has a 12 month low of $1.21 and a 12 month high of $3.77.

Analyst Ratings Changes

A number of research analysts have weighed in on EDAP shares. Wall Street Zen began coverage on shares of EDAP TMS in a research report on Thursday, May 15th. They set a "hold" rating on the stock. Piper Sandler lowered shares of EDAP TMS from an "overweight" rating to a "neutral" rating in a research note on Thursday, May 15th. One equities research analyst has rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. According to MarketBeat.com, EDAP TMS currently has a consensus rating of "Hold" and an average price target of $8.50.

About EDAP TMS

EDAP TMS SA is a holding company, which, through its subsidiary, engages in the development, production, and marketing of minimally invasive medical devices for urological diseases. It operates through the High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS) segments. The HIFU segment develops, manufactures, and markets devices for the minimally invasive ablation of certain types of localized tumors using HIFU technology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.